Navigation Links
Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform

ORMD 0901 is Being Developed as an Oral Dosage Form of a GLP1-analog Aimed

at Improving Glycemic Control in Adults With Type 2 Diabetes

JERUSALEM, Israel, September 16 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of oral drug delivery systems, announced today that it has launched pre-clinical trials of ORMD 0901, a GLP1-analog.

ORMD 0901 belongs to the Incretin family of drugs which helps to manage diabetes, including reduction in blood glucose levels and inhibiting glucagon secretion.

Incretins have been cited in causing regeneration of pancreatic insulin secreting cells, and in tissue protective properties including protection of the heart. GLP1 and analogs are associated with gradual weight loss, which is very desirable in diabetes patients.

"The launch of pre-clinical trials of ORMD 0901 and expansion of Oramed's platform marks the next strategic milestone for our company as we demonstrate the effectiveness of our oral delivery technology in yet another important family of polypeptide drugs for diabetes, that are until now only available in injection form," said Oramed CEO Nadav Kidron.

We plan to conduct the ORMD 0901 trials at Hadassah University Medical Center and they are expected to conclude by the end of 2008.

Oramed plans to launch phase 2b trials of ORMD 0801, its oral insulin capsule, in India in the first quarter of 2009.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit

Forward-looking statements

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward looking statements. The company undertakes no obligation to update or revise any forward-looking statements.

Company and Investor Relation Contacts:

Oramed Pharmaceuticals

Eric Rosenberg

Cell: +972-54-566-7713

Office: +972-2-566-0001


Media Contacts:

Ruder Finn Israel for Oramed

Matthew Krieger

Cell: +972-54-467-6950

Office: +972-2-589-2003


SOURCE Oramed Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
2. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
3. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
(Date:10/9/2015)... LAUSANNE , Schweiz, October 9, 2015 Der ... geht an Dr.   Yutaka Kondo und Dr.   ... JCA-Mauvernay Award   2015 " geht an Dr.   ... --> Der " JCA-Mauvernay Award   ... und Dr.   Junko Takita    ™ ...
(Date:10/8/2015)... England and PITTSBURGH , ... ), a leading global pharmaceutical company, will host a ... at 5:00 pm ET to review the value ... (NYSE: PRGO ; TASE) through Mylan,s offer to ... a comprehensive presentation which outlines the compelling proposition for ...
(Date:10/8/2015)... , Oct. 8, 2015  The National Heart, ... $40 million to the Broad Institute of MIT ... of 20,000 individuals, as well as data to ... profiling. Trans-Omics for Precision Medicine ... toward a larger initiative, which will use whole ...
Breaking Medicine Technology:
... Cephalon, Inc. (Nasdaq: CEPH ) today provided notice ... Notes due 2014 (the "2014 Notes") and 2.00 percent ... in respect of the Merger (as defined below) of ... Industries Ltd., an Israeli corporation ("Parent"), the consummation of ...
... The Plasma Protein Therapeutics Association (PPTA) ... temporary and proposed regulations implementing the ... and fails to take into account concerns expressed ... narrow definition of an "orphan drug" disproportionally affects ...
Cached Medicine Technology:
(Date:10/10/2015)... FLA. (PRWEB) , ... October 10, 2015 , ... In ... has been named the Best Place To Work in Jacksonville, amongst medium-sized companies with ... September 27th and was followed up with a celebratory gala on October 1st. ...
(Date:10/9/2015)... Los Angeles, CA (PRWEB) , ... October 09, 2015 , ... ... awareness for breast cancer victims, survivors, and the ongoing effort to find a cure. ... patients another outlet for helping women in need. With their Bra Collection Campaign, Beverly ...
(Date:10/9/2015)... ... ... Smoke alarms can save lives. In fact, according to the National Fire ... home fires in half. As part of Fire Prevention Week, Amica Insurance ... , Half of home fire deaths result from fires reported between 11 p.m. and ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... company, has announced the final product specifications for TRACTUS, the world’s first sterile ... in the United States in response to the FDA’s recent Unique Device Identifier ...
(Date:10/9/2015)... ... October 09, 2015 , ... Cambias Insurance Agency, a family ... initiating a combined charity effort with Animal Rescue New Orleans in an effort ... , Animal Rescue New Orleans is a non-profit organization committed to rescuing and ...
Breaking Medicine News(10 mins):
... so does survival, study finds , MONDAY, Feb. 8 (HealthDay ... with increased risk of death, researchers say. , In a ... again at age 89 in a group of 555 participants ... at 85 and 89 years, and a greater decline in ...
... ... Strash, FACHE, Chief Executive Officer with Oro Valley Hospital, on critical issues facing healthcare ... ... timely communication among different segments of the medical community, Jackson & Coker ( ...
... , CINCINNATI , Feb. 8 Three ... "about right," according to a study of more than 65,000 ... of obesity over the past several years, the number of ... 1999 and 2007," says Nicholas M. Edwards , MD, ...
... triggering bone formation , MONDAY, Feb. 8 (HealthDay News) -- ... osteoporosis in lab mice and rats, a new study has ... gut hinders bone formation. Most current drugs for osteoporosis only ... "New therapies that inhibit the production of serotonin in the ...
... BETHESDA, Md. , Feb. 8 /PRNewswire-Asia/ ... Western healthcare,products and services in the People,s Republic of China , today ... , , Financial Highlights:, -- Revenue in ... over year to $46.5 million;, -- Net ...
... ... McDonald, have formed One2One Partners. The firm creates customized programs that strengthen the relationship ... an engaged workforce and minimize the threat of third-party intervention, regardless of potential legislation ... ...
Cached Medicine News:
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
... Eliminate aerosol contamination, which ... in PCR. Hydrophobic, nonwicking ... air can pass through ... in contrast to tips ...
Dnase-free, with an integral filter to protect against carry over and contamination from aerosols...
Medicine Products: